Skip to main content
. 2016 Aug 1;36(6):731–745. doi: 10.1038/onc.2016.242

Figure 2.

Figure 2

hsa-mir-372 expression increase proliferation and EGFR-TKI sensitivity. (a) Relative expression of miR-372-3p in four different NSCLC cell line models stably transduced for hsa-mir-372 expression as measured by RT–qPCR. As a reference, endogenous expression of miR-372-3p in the testicular germ cell cancer cell line 833KE was also measured. (b) Analysis of hsa-mir-372 impact on cell cycle distribution indicates a general trend where hsa-mir-372 expression results in a decrease in the G0/G1 population, and an increase of the S and G2/M populations. (c) In three out of four cell line models, hsa-mir-372 expression resulted in an increased proliferation index. (d) Expression of hsa-mir-372 results in increased sensitivity to EGFR-targeting therapy (gefitinib, 10 uM) as shown for A549, NCI-H1703 and U1810 cells using clonogenic assay. Throughout the figure, bars represent mean values of three replicate experiments, error bars indicate standard deviation, P-value calculation was performed by t-test and reported as follows: P>0.05(NS), P<0.05(*), P<0.01(**) and P<0.001(***).